Tag: Johnson & Johnson

U.S. Justice Department Pursue Investigation over Cancer Risk in J&J’s Powder

The U.S. Justice Department is pursuing a criminal investigation into whether Johnson & Johnson lied to the public about the possible cancer risks of its talcum powder, people with knowledge of th...

Celsius and Janssen in Collaboration

Celsius Therapeutics announced a collaboration with Janssen Biotech. Under the terms of the agreement, Celsius will apply its proprietary single-cell genomics and machine learning platform to identify...

Johnson & Johnson Announced Results from the Phase 3 Study of XARELTO®

johnson&johnson
The Janssen Pharmaceutical Companies of Johnson & Johnson announced new results from the Phase 3 EINSTEIN-Jr study, showing pediatric patients (aged birth to 17 years) treated with XARELTO® (rivar...

J&J’s INVOKANA Significantly Reduced Major Cardiovascular Events and Kidney Failure

johnson & johnson
The Janssen Pharmaceutical Companies of Johnson & Johnson announced results of a new subgroup analysis from the landmark phase 3 CREDENCE study, showing INVOKANA® (canagliflozin) significantly red...

J&J Published Data from Phase 3 DARZALEX® Study

The Janssen Pharmaceutical Companies of Johnson & Johnson announced the publication of data from the randomized, open-label Phase 3 MAIA (MMY3008) study that showed DARZALEX® (daratumumab) plus le...

J&J Used Underhanded Tactics to Fend Off Generics

Johnson & Johnson’s blockbuster cancer med Zytiga only recently lost its shield against generic competition, and according to a new lawsuit, that’s because J&J used underhanded tactics to ke...

J&J Presented Early Results from First-In-Human Study of Monarch™ Platform

johnson & johnson
Auris Health, Inc., part of Johnson & Johnson Medical Devices Companies, announced early positive results from an ongoing study designed to evaluate the safety and feasibility of the Monarch Platf...

Janssen Submitted Application for ERLEADA Approval

johnson & johnson
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking approv...

Xarelto’s Sales Drop as Competition Pile Up

bayer
After a rough year for Bayer and Johnson & Johnson's anticoagulant Xarelto, the companies hoped the competition would take it easy in 2019. Pfizer and Bristol-Myers Squibb's Eliquis had other plan...

Johnson & Johnson Beats Estimates on Pharma Strength, Raises Sales Forecast

johnsonandjohnson
Johnson & Johnson beat quarterly profit estimates on Tuesday and raised its adjusted sales growth forecast for the year, driven by demand for its treatment for psoriasis and Crohn’s disease and ca...

J&J Completes Acquisition of Auris Health

johnson & johnson
Johnson & Johnson announced that Ethicon, Inc., has completed the acquisition of Auris Health, Inc. for approximately $3.4 billion in cash. Additional contingent payments of up to $2.35 billion, i...

Janssen and Australian Institute Collaborate to Prevent PPH

Janssen Pharmaceutica N.V, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced that it has entered into a sponsored research agreement with the Monash Institute of Pharmace...

Monthly and Daily Treatment of HIV-1 Showed Same Efficacy

Johnson & Johnson’s subsidiary Janssen Pharmaceuticals and ViiV Healthcare have revealed 48 week data from two pivotal Phase III trials showing injections of their long-acting, monthly combination...

Big Pharma Answered for High Prices

U.S. senators called drug pricing practices “morally repugnant” and told drug company executives they do not want to hear them blame others for the high prices, taking an aggressive stance at a Senate...

J&J Acquires Auris Health for $3.4b

Auris Health’s Robotic Platform Expands Johnson & Johnson’s Digital Surgery Portfolio. Focused on creating the next frontier of surgery, Johnson & Johnson, announced that Ethicon, Inc., ent...

Philogen and Janssen Discover New Molecular Therapy

Philogen S.p.A., a privately-owned biotechnology company, today announced through its wholly-owned Swiss subsidiary, Philochem AG, a collaboration agreement with Janssen Biotech, Inc., one of the Jans...